Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 29, 2016. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific share transaction and does not contain consolidated financial statements.
Material Changes
The filing details a share acquisition by Ms. C Thomas, a PDMR, resulting from the re-investment of dividends paid on April 14, 2016, under the GSK 2009 Deferred Annual Bonus Plan Post-Tax. The shares were acquired at a price of 1496.49 pence per share.
- Personal Contribution Element: 79.640 Ordinary Shares acquired.
- Matching Element (GSK Contribution): 80.073 Ordinary Shares acquired.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a director's share transaction.
Investor Verification Points
- Verify the total number of shares acquired by Ms. C Thomas (159.713 shares) and the specific price per share (1496.49 pence).
- Confirm the source of the acquisition was the re-investment of dividends under the 2009 Deferred Annual Bonus Plan Post-Tax.
- Note that this filing does not contain financial performance data for the period; refer to Form 20-F or quarterly earnings releases for financial metrics.